FindTrial
Sign In

Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma

Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220141
Enrollment
Unknown
Registered
2005-10-11
Start date
2005-10-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

investigational material(s) Generic name etc : Omalizumab INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational mat

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria - Allergic asthma patients - Inadequately controlled patients Exclusion Criteria - History of severe anaphylactoid or anaphylactic reactions - Previous treatment with omalizumab - History of cancer or cancer Other protocol-defined exclusion criteria may apply.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety/Efficacy Primary outcomes: Safety of omalizumab Secondary Outcomes: Pulmonary function parameters measured by spirometer; Morning and evening peak expiratory flow (PEF); Symptom score, treatment score, activities of daily living score, nighttime sleep score, and asthma score—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026